| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) |
| 06 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies |
| 18 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis |
| 28 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of July 26, 2026, between Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages ... |
| 16 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR |
| 03 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2026, between Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages ... |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 |
| 04 Mar 2026 |
8-K: Regulation FD Disclosure
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis |
| 09 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 |
| 04 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of February 3, 2026 (the “Effective Date”), by and between (i) OPKO Biologics Ltd., an Israeli company with offices at 16 Ashlegan St., K... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study |
| 08 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment |
| 28 Jul 2025 |
8-K: Regulation FD Disclosure; Other Events
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis |
| 18 Jul 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), held its 2025 Annual Meeting of Shareholders on July 16, 2025 (the “Annual Meeting”). The final voting results for the proposals submitted to a v... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
JERUSALEM, May 9th 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. |
| 28 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
JERUSALEM, March 28 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. |
| 17 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of March 16, 2025 (the “Effective Date”), by and between (i) OPKO Biologics Ltd., an Israeli company with offices at 16 Ashlegan St., Kiryat Gat 8211804, Isra... |
Loading...